Advertisement
BLCO vs IDXX
Which Stock Would AI Choose? Bausch + Lomb (BLCO) vs. IDEXX Laboratories (IDXX) Stock Comparison
Key Takeaways
- Bausch + Lomb (BLCO) is a global eye-health company turning around profitability, while IDEXX Laboratories (IDXX) is a profitable animal-health diagnostics leader with recurring revenue.
- BLCO trades at a modest valuation with a market cap near $6 billion, whereas IDXX commands a premium multiple on a roughly $40 billion market cap.
- Both companies raised full-year guidance in recent quarters, but IDXX delivered stronger profit margins and earnings growth.
- IDXX has faced softer momentum from weaker U.S. veterinary clinic visits, while BLCO is working through a deleveraging and efficiency program.
- Analyst consensus is broadly constructive on both names, yet the two stocks offer very different risk-reward profiles.
Introduction
This stock comparison examines two healthcare companies with little product overlap but shared exposure to resilient consumer and healthcare spending: Bausch + Lomb (BLCO) and IDEXX Laboratories (IDXX). BLCO is a diversified eye-health business spanning contact lenses, ophthalmic pharmaceuticals, and surgical devices, while IDXX is a leader in companion-animal diagnostics, water testing, and livestock testing. Investors weighing a turnaround-oriented value story against a higher-quality growth franchise may find the relative performance and market positioning of these two names instructive, particularly as both navigate shifting demand trends and evolving analyst sentiment.
BLCO Overview and Recent Performance
Bausch + Lomb (BLCO) is a global eye-health company operating across vision care, surgical, and ophthalmic pharmaceuticals segments. It was spun off from parent Bausch Health in 2022. In recent market activity, the company reported revenue growth near 9% year over year, with losses narrowing as its dry-eye portfolio, premium intraocular lenses, and daily contact lenses gained traction. Management has modestly raised full-year revenue guidance, and the company secured a European CE Mark for its next-generation SeeLyra femtosecond laser, supporting its surgical portfolio.
Sentiment has been shaped by both encouraging commercial execution and lingering concerns, including a substantial debt load and a valuation discount that some investors attribute to balance-sheet and governance considerations. Analysts have maintained a broadly favorable stance, with several firms reaffirming Buy ratings and price targets above recent trading levels, while the stock's year-to-date gains have lagged the broader market.
IDXX Overview and Recent Performance
IDEXX Laboratories (IDXX) is a global leader in veterinary diagnostics and software, generating most of its revenue from the Companion Animal Group (CAG), with smaller water and livestock, poultry, and dairy testing segments. Recent quarters showed double-digit revenue and earnings growth, driven by recurring diagnostics revenue, expanded instrument placements, and innovation such as the inVue Dx and Cancer Dx platforms. The company raised its full-year earnings outlook and delivered expanding gross and operating margins.
Relative performance has been more muted, however, as softer U.S. veterinary clinical visit trends and foreign-exchange headwinds have weighed on sentiment. Despite consistently beating earnings estimates, the stock has declined over the past year, trading at a premium valuation that leaves limited room for disappointment. Analysts remain constructive, with several maintaining Buy ratings and price targets implying meaningful upside, even as some firms have trimmed targets on pricing concerns across the broader animal-health sector.
Trending AI Robots
For traders seeking a systematic edge in evaluating opportunities like BLCO and IDXX, Tickeron's Trending AI Robots page offers a curated view of its most compelling automated strategies. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, but only those best suited to current market conditions earn a place in this featured section. These bots span a wide range of trading styles, strategies, timeframes, performance statistics, and ticker sets, allowing users to compare approaches rather than rely on a single signal. Browsing the Trending AI Robots can help investors explore how algorithmic systems are currently positioned across different names and market environments.
Head-to-Head Comparison
Although both companies operate in healthcare, their business models differ sharply. BLCO (BLCO) depends on consumer eye-health demand, pharmaceutical launches, and surgical device adoption, with profitability still rebuilding under an efficiency program. IDXX (IDXX) relies on a high-margin, recurring "razor-and-razorblade" diagnostics model, where installed instruments drive ongoing consumables revenue.
Growth drivers also diverge. BLCO's catalysts include premium intraocular lenses, dry-eye therapies, and geographic expansion of its surgical portfolio. IDXX's catalysts center on diagnostic innovation, software adoption, and international market penetration. On risk factors, BLCO carries elevated leverage and narrower profitability, while IDXX faces valuation sensitivity, U.S. clinic-visit weakness, and currency exposure. Recent momentum has favored BLCO in relative terms over recent weeks, yet IDXX offers stronger earnings quality and more consistent margin expansion.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings quality, and relative positioning, Tickeron's AI would likely lean toward IDXX (IDXX) on a fundamental-strength basis, given its recurring revenue, expanding margins, and durable growth catalysts. However, the momentum and valuation dimensions appear more favorable for BLCO (BLCO), which trades at a discount and has shown recent upward trajectory. The verdict is therefore probabilistic rather than definitive: an AI framework may favor IDXX for trend stability and profitability, while flagging BLCO as the higher-risk, potentially higher-reward turnaround candidate. Traders should weigh these contrasting profiles against their own objectives.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BLCO is a StrongBuy and IDXX is a StrongBuy.
BLCO in upward trend: price may jump up because it broke its lower Bollinger Band on October 12, 2026
BLCO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 26 of 30 cases where BLCO's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BLCO's RSI Oscillator exited the oversold zone, 17 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 65%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on BLCO as a result. In 66 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for BLCO just turned positive on October 21, 2026. Looking at past instances where BLCO's MACD turned positive, the stock continued to rise in 30 of 49 cases over the following month. The odds of a continued upward trend are 61%.
BLCO moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where BLCO advanced for three days, in 159 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The 10-day moving average for BLCO crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BLCO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
The Aroon Indicator for BLCO entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.976) is normal, around the industry mean (4.961). P/E Ratio (-36.312) is within average values for comparable stocks, (37.232). Projected Growth (PEG Ratio) (0.888) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.139) is also within normal values, averaging (56.876).
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. BLCO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BLCO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Momentum Indicator for IDXX turns positive, indicating new upward trend
IDXX saw its Momentum Indicator move above the 0 level on October 14, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned positive. In 56 of the 93 cases, the stock moved higher in the following days. The odds of a move higher are at 60%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for IDXX just turned positive on September 22, 2026. Looking at past instances where IDXX's MACD turned positive, the stock continued to rise in 19 of 41 cases over the following month. The odds of a continued upward trend are 46%.
IDXX moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for IDXX crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 22 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 59%.
Following a +5.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where IDXX advanced for three days, in 174 of 289 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDXX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
IDXX broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IDXX entered a downward trend on September 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating fairly steady price growth. IDXX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (27.689) is normal, around the industry mean (66.046). P/E Ratio (39.606) is within average values for comparable stocks, (2.422). Projected Growth (PEG Ratio) (2.894) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (9.042) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IDXX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
IDXX | ||
|---|---|---|
OUTLOOK RATING 1..100 | 32 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 81 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 16 | |
PRICE GROWTH RATING 1..100 | 49 | |
P/E GROWTH RATING 1..100 | 71 | |
SEASONALITY SCORE 1..100 | 2 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| BLCO | IDXX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 65% | 2 days ago 73% |
| Stochastic ODDS (%) | 2 days ago 83% | 2 days ago 74% |
| Momentum ODDS (%) | 2 days ago 71% | 2 days ago 60% |
| MACD ODDS (%) | 2 days ago 61% | 2 days ago 46% |
| TrendWeek ODDS (%) | 2 days ago 68% | 2 days ago 61% |
| TrendMonth ODDS (%) | 2 days ago 73% | 2 days ago 53% |
| Advances ODDS (%) | 2 days ago 66% | 8 days ago 60% |
| Declines ODDS (%) | 11 days ago 67% | 17 days ago 69% |
| BollingerBands ODDS (%) | 2 days ago 87% | 2 days ago 77% |
| Aroon ODDS (%) | 2 days ago 78% | 2 days ago 68% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BLCO’s FA Score shows that 1 FA rating(s) are green while IDXX’s FA Score has 1 green FA rating(s).
- BLCO’s FA Score: 1 green, 4 red.
- IDXX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BLCO’s TA Score shows that 6 TA indicator(s) are bullish while IDXX’s TA Score has 5 bullish TA indicator(s).
- BLCO’s TA Score: 6 bullish, 4 bearish.
- IDXX’s TA Score: 5 bullish, 5 bearish.
Price Growth
BLCO (@Pharmaceuticals: Other) experienced а +4.62% price change this week, while IDXX (@Medical Specialties) price change was +3.58% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.86%. For the same industry, the average monthly price growth was -3.31%, and the average quarterly price growth was +7.53%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +1.54%. For the same industry, the average monthly price growth was -5.91%, and the average quarterly price growth was +42.02%.
Reported Earning Dates
BLCO is expected to report earnings on Oct 28, 2026.
IDXX is expected to report earnings on Nov 02, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+2.86% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (+1.54% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
BLCO and
Correlation & Price change
A.I.dvisor indicates that over the last year, BLCO has been loosely correlated with ICUI. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if BLCO jumps, then ICUI could also see price increases.
| Ticker / NAME | Correlation To BLCO | 1D Price Change % | ||
|---|---|---|---|---|
| BLCO | 100% | +1.46% | ||
| ICUI - BLCO | 48% Loosely correlated | +4.66% | ||
| COO - BLCO | 45% Loosely correlated | +4.54% | ||
| CRL - BLCO | 45% Loosely correlated | -1.51% | ||
| MTD - BLCO | 44% Loosely correlated | +0.40% | ||
| RVTY - BLCO | 44% Loosely correlated | +0.48% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| VDC | 243.57 | 7.55 | +3.20% |
| Vanguard Consumer Staples ETF (VDC) | |||
| UPAR | 15.37 | 0.04 | +0.26% |
| UPAR Ultra Risk Parity ETF (UPAR) | |||
| HYXF | 44.91 | 0.05 | +0.11% |
| iShares ESG Advanced High Yield Corporate Bond ETF (HYXF) | |||
| DWM | 73.00 | -0.79 | -1.07% |
| WisdomTree International Equity Fund (DWM) | |||
| ENHU | 28.47 | -0.39 | -1.33% |
| iShares Enhanced Large Cap Core Active ETF (ENHU) | |||